QuickView for SCN2A;jsessionid=0B02C1D8215C8B1198A007FB6181BEB0;jsessionid=AD1D6739EE0D85F1B0819A8AEF12F3BC (gene)

1. Epilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties.
2. Inhibitory effect of atomoxetine on Nav1.2 voltage-gated sodium channel currents.
3. Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons.
4. A mutation in the neonatal isoform of SCN2A causes neonatal-onset epilepsy.
5. Functional correlates of clinical phenotype and severity in recurrent SCN2A variants.

There were no clinical trials for SCN2A;jsessionid=0B02C1D8215C8B1198A007FB6181BEB0;jsessionid=AD1D6739EE0D85F1B0819A8AEF12F3BC